Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.30 |
| ▸ | RELA | Q04206 | 1/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7345119 | 0.82 | HDAC1 (0.31) | HDAC6HDAC1HDAC2PAX8 | |
| SCHEMBL8737769 | 0.81 | HDAC6 (0.39) | HDAC6HDAC1HDAC2DGAT1NFKB1 | |
| SCHEMBL3126231 | 0.77 | DGAT1 (0.38) | HDAC6HDAC1HDAC2DGAT1CA14 | |
| SCHEMBL432112 | 0.77 | HDAC6 (0.37) | HDAC6HDAC1HDAC2DGAT1NFKB1 | |
| SCHEMBL28676568 | 0.75 | HDAC6 (0.36) | HDAC6HDAC1HDAC2DGAT1CA14 | |
| SCHEMBL8098483 | 0.75 | HDAC6 (0.40) | HDAC6HDAC1HDAC2DGAT1CA14 | |
| SCHEMBL9873641 | 0.75 | HDAC6 (0.36) | HDAC6HDAC1HDAC2DGAT1CA14 | |
| Hydrochloric Acid SCHEMBL5679482 | 0.75 | HDAC6 (0.36) | HDAC6HDAC1HDAC2DGAT1CA14 | |
| SCHEMBL22143232 | 0.74 | HDAC6 (0.33) | HDAC6HDAC1HDAC2DGAT1CA14 | |
| SCHEMBL2719 | 0.74 | HDAC6 (0.33) | HDAC6HDAC1HDAC2DGAT1CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7632840-B2 | Quinazoline compounds for the treatment of hyperproliferative disorders | ASTRAZENECA AB (SE) | 2009-12-15 | — | — | US | disclosed |
| EP-1713781-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-11-05 | — | — | EP | disclosed |
| US-20080058391-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-03-06 | — | — | US | disclosed |
| US-20070293490-A1 | Quinazoline Derivatives | ASTRAZENECA AB (SE) | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058391-A1 | NOVEL COMPOUNDS | HCN3, KCNN3, HCN4 | HDAC6 1919/4885HDAC1 1488/4885HDAC2 2156/4885 |
| US-20070293490-A1 | Quinazoline Derivatives | CCNA1, CCND3, CCND2 | HDAC6 3097/4885HDAC1 1592/4885HDAC2 2844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.